Oxygent


Also found in: Wikipedia.

Oxygent

A perflubron-based synthetic blood substitute which, while it was more effective than Fluosol in transporting O2, nonetheless failed in clinical trials and is not FDA-approved for use in humans.
References in periodicals archive ?
New Alliance Pharmaceuticals is holder of an exclusive licence for perfluorocarbon product Oxygent, whose extensive clinical history will earn Sanguine a leading position in oxygen therapy research and development, according to Sanguine's president, Frank Marra.
New Alliance PharmaceuticalsA is holder ofA an exclusive licence for perfluorocarbon product Oxygent, whose extensive clinical history will earn Sanguine a leading position in oxygen therapy research and development, according to Sanguine's president, Frank Marra.
New Alliance reportedly holds an exclusive license for Oxygent, the most clinically advanced perfluorocarbon (PFC) product in the world, with 20 clinical studies and ~250 preclinical studies already completed.
Gilderod HR, Adams P (1983) Diurnal variations in the oxygent content and acid requement of recirculating nutrients solutions and it the uptake of water and potassium by cucumber and tomato plants.
Alliance, founded in 1989, is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent. Alliance is currently the only company that has advanced a synthetic PFC emulsion-based oxygen therapeutic into late-stage multi-center international clinical trials in both Europe and North America.
Oxygent is being developed by Alliance in the United States, Canada, and Europe in conjunction with Baxter.
"We unfortunately have to take a little time out here in our clinical development before we forge ahead, but this is a huge market that's not going away," says Peter Keipert, director of Oxygent development at Alliance.
Oxygent is being developed in the United States, Canada, and Europe in conjunction with Baxter Healthcare Corporation.
A product called Oxygent, developed in the 1 990s by Alliance Pharmaceutical Corporation, San Diego, CA, seems to have overcome these obstacles.
A product called Oxygent, developed in the 1990s by Alliance Pharmaceutical Corporation, San Diego, CA, seems to have overcome these obstacles.
But a new fluorocarbon-based blood substitute, called Oxygent, uses bromo-perfluoro-octane, a fluorocarbon that is quickly excreted by the lungs.
Perflubron emulsion (Oxygent [TM]) is now in advanced clinical trials as a non-hemoglobin, oxygen-carrying blood substitute and is expected to be in clinical use soon.